Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells ; volume:166 ; number:1 ; day:7 ; month:1 ; year:2024 ; pages:99-112 ; date:1.2024
Journal of neuro-oncology ; 166, Heft 1 (7.1.2024), 99-112, 1.2024
- Urheber
-
Zeuner, Simon
Vollmer, Johanna
Sigaud, Romain
Oppermann, Sina
Peterziel, Heike
ElHarouni, Dina
Oehme, Ina
Witt, Olaf
Milde, Till
Ecker, Jonas
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11060-023-04526-w
- URN
-
urn:nbn:de:101:1-2024040911091797439303
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zeuner, Simon
- Vollmer, Johanna
- Sigaud, Romain
- Oppermann, Sina
- Peterziel, Heike
- ElHarouni, Dina
- Oehme, Ina
- Witt, Olaf
- Milde, Till
- Ecker, Jonas
- SpringerLink (Online service)
Ähnliche Objekte (12)
Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma
Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137
Overcoming multiple drug resistance mechanisms in medulloblastoma
Overcoming multiple drug resistance mechanisms in medulloblastoma
Bcl-XL but Not Bcl-2 is a potential target in medulloblastoma therapy
Selective targeting of histone deacetylases in MYC amplified Group 3 medulloblastoma
The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
A functional genomics approach to identify pathways of drug resistance in medulloblastoma
A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma
Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells
Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma
Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma
Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137
Overcoming multiple drug resistance mechanisms in medulloblastoma
Overcoming multiple drug resistance mechanisms in medulloblastoma
Bcl-XL but Not Bcl-2 is a potential target in medulloblastoma therapy
Selective targeting of histone deacetylases in MYC amplified Group 3 medulloblastoma
The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
A functional genomics approach to identify pathways of drug resistance in medulloblastoma
A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma
Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells
Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma
Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma
Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137
Overcoming multiple drug resistance mechanisms in medulloblastoma
Overcoming multiple drug resistance mechanisms in medulloblastoma
Bcl-XL but Not Bcl-2 is a potential target in medulloblastoma therapy
Selective targeting of histone deacetylases in MYC amplified Group 3 medulloblastoma
The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
A functional genomics approach to identify pathways of drug resistance in medulloblastoma
A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma
Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells